STOCK TITAN

iSpecimen Inc. - ISPC STOCK NEWS

Welcome to our dedicated page for iSpecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on iSpecimen stock.

iSpecimen Inc., headquartered in Lexington, MA, is a leading marketplace for human biospecimens. The company provides researchers with the specimens they need from the patients they want through its innovative iSpecimen Marketplace. This online platform connects healthcare organizations with access to patients and specimens with scientists in need of these vital resources.

Utilizing proprietary, cloud-based technology, iSpecimen enables researchers to intuitively search for specimens across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. This system allows for easy and compliant access to specimens, facilitating scientific discovery and advancing healthcare for all.

iSpecimen stands out by offering a unique value proposition to both researchers and partner sites. Researchers gain the necessary resources to drive their studies, while partner sites can contribute to biomedical discovery and benefit financially. The company caters to a global market, with operations spanning the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority of its revenue coming from the Americas.

In recent news, iSpecimen has achieved a sequential quarterly revenue growth of 75%, driven by enhanced operational efficiencies and new business initiatives. The company continues to expand its network by adding new suppliers and reinforcing existing relationships to provide researchers with increased access to highly sought-after biospecimens, especially for oncology research. Additionally, iSpecimen is making strides in quality control and assurance through digital AI histopathology services, enhancing data quality and operational efficiency.

For investors and media inquiries, iSpecimen's contacts at KCSA Strategic Communications are available for further information.

Rhea-AI Summary
iSpecimen Inc. (ISPC) will report its financial results for the full year ended December 31, 2023, before the market opens on March 13, 2024. A conference call and webcast featuring remarks by CEO Tracy Curley will follow at 8:30 a.m. Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
conferences earnings
-
Rhea-AI Summary
iSpecimen Inc. partners with TriMetis Life Sciences to enhance quality control and assurance through digital AI histopathology services. The partnership aims to revolutionize tissue assessment for preclinical research by utilizing AI-powered solutions to standardize and enhance tissue sample evaluation, focusing on solid tumor types. This initiative will integrate technology solutions from TriMetis into iSpecimen's platform, providing researchers and suppliers access to critical data and AI-enhanced information. The partnership seeks to streamline procurement processes, increase accuracy, and reduce delays, ultimately cutting costs and delivering better outcomes for patients worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
partnership
-
Rhea-AI Summary
iSpecimen Inc. (ISPC) will participate in the Maxim Group Virtual Healthcare IT Conference on January 25, 2024. Tracy Curley, CEO, will present at 10:00 a.m. ET. The company connects scientists with healthcare specimen providers for medical research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
conferences
Rhea-AI Summary
iSpecimen Inc. (ISPC) expands its provider network to offer researchers increased access to highly-sought-after biospecimens for oncology research, adding new suppliers, expanding existing relationships, and introducing new offerings. The expansion includes access to specimens from cancer patients in different treatment stages, with specific biomarkers and mutations, across various tissue types and biofluid formats. The company also supports liquid biopsy research and offers custom collections with increased delivery options. iSpecimen continues to utilize next generation sequencing as part of the recent cancer sequencing procurement program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.78%
Tags
none
-
Rhea-AI Summary
iSpecimen Inc. (Nasdaq: ISPC) reported a sequential quarterly revenue growth of 75% driven by enhanced operational efficiencies and new business initiatives. Revenue for Q3 2023 was $2.8 million, a 75% increase from Q2 2023. The company also saw a 122% increase in the conversion of quotes to purchase orders. Unique supplier organizations under agreement increased to 234, and unique customer organizations increased to 603. iSpecimen Marketplace had 7,326 registered users, a 15% increase from last year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.63%
Tags
-
Rhea-AI Summary
iSpecimen Inc. has added new infectious disease specimen providers to its global supply network, expanding access to essential human tissue and biofluids for infectious disease research. The collaboration will provide researchers with access to clinically collected samples, banked tissues, and custom collections of biospecimens. iSpecimen's CEO, Tracy Curley, stated that the company's network and custom project capabilities will support diagnostic test and treatment development, leading to improved patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
none
Rhea-AI Summary
iSpecimen Inc. announces preliminary financial results for Q3 2023, expecting revenue between $2.6 to $2.8 million, a 60-70% increase from Q2 2023. The launch of the next-day quote program has driven higher financial performance, with a 122% conversion increase from quotes to purchase orders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.58%
Tags
-
Rhea-AI Summary
iSpecimen Inc. introduces next-day quote service to accelerate biospecimen transactions, delivering accurate pricing within 24 hours of request.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
iSpecimen expands provider network to advance women's health research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
Rhea-AI Summary
iSpecimen focuses on core revenue drivers, expense reductions, and new revenue growth opportunities. Immediate headcount reductions of approximately 20% of the workforce. Monthly expenses expected to decrease by approximately 29% and 52%. Launch of virtual cancer sequencing procurement program to provide researchers with consistent access to tumor tissues. Strong demand for these samples.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
none

FAQ

What is the current stock price of iSpecimen (ISPC)?

The current stock price of iSpecimen (ISPC) is $4.464 as of November 1, 2024.

What is the market cap of iSpecimen (ISPC)?

The market cap of iSpecimen (ISPC) is approximately 3.5M.

What is iSpecimen Inc.?

iSpecimen Inc. is a marketplace for human biospecimens, connecting researchers with specimens from healthcare organizations via an online platform.

Where is iSpecimen Inc. headquartered?

iSpecimen Inc. is headquartered in Lexington, MA.

How does the iSpecimen Marketplace work?

The iSpecimen Marketplace uses proprietary cloud-based technology to connect researchers with specimens from a network of healthcare organizations.

What kind of specimens does iSpecimen provide?

iSpecimen provides human biofluids, solid tissues, and hematopoietic stem and immune cells for research purposes.

What recent achievements has iSpecimen made?

iSpecimen has seen a 75% sequential quarterly revenue growth and expanded its network to offer more biospecimens, especially for oncology research.

Who can benefit from using iSpecimen's services?

Both life science researchers who need biospecimens and healthcare organizations that provide these specimens can benefit from iSpecimen's services.

What regions does iSpecimen operate in?

iSpecimen operates globally, with a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

How can researchers access iSpecimen's services?

Researchers can access iSpecimen's services through their online marketplace, which allows for intuitive search and compliant access to specimens.

How does iSpecimen ensure quality control?

iSpecimen utilizes digital AI histopathology services to enhance quality control and assurance, ensuring superior data quality and operational efficiency.

How can investors get in touch with iSpecimen?

Investors can contact iSpecimen through KCSA Strategic Communications via the provided email addresses.

iSpecimen Inc.

Nasdaq:ISPC

ISPC Rankings

ISPC Stock Data

3.53M
830.00k
21.32%
3.96%
1.29%
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States of America
LEXINGTON